regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
== Case Study: Ocean Euxinia == Because green-pigmented green sulfur bacteria require higher light intensities than their brown-pigmented counterparts, the presence of chlorobactane in the rock record has been used as key evidence in interpretations for a very shallow euxinic layer in the ocean. The euxinic zone may have changed depth in the ocean at various points in Earth's history, such as with the advent of an oxygenated atmosphere around 2.45 billion years ago and the shallowing of the oxic zone within the last six kyr.
In response to doubts about the lack of nuclear products, cold fusion researchers have tried to capture and measure nuclear products correlated with excess heat. Considerable attention has been given to measuring 4He production. However, the reported levels are very near to background, so contamination by trace amounts of helium normally present in the air cannot be ruled out. In the report presented to the DOE in 2004, the reviewers' opinion was divided on the evidence for 4He, with the most negative reviews concluding that although the amounts detected were above background levels, they were very close to them and therefore could be caused by contamination from air. One of the main criticisms of cold fusion was that deuteron-deuteron fusion into helium was expected to result in the production of gamma rays—which were not observed and were not observed in subsequent cold fusion experiments. Cold fusion researchers have since claimed to find X-rays, helium, neutrons and nuclear transmutations. Some researchers also claim to have found them using only light water and nickel cathodes. The 2004 DOE panel expressed concerns about the poor quality of the theoretical framework cold fusion proponents presented to account for the lack of gamma rays.
Darbar ( transl. Court) is a 2020 Indian Tamil-language action thriller film written and directed by AR Murugadoss, and produced by Allirajah Subaskaran under the banner Lyca Productions. The film stars Rajinikanth, Suniel Shetty, Nayanthara and Nivetha Thomas. It follows Aaditya Arunasalam (Rajinikanth), the commissioner of Mumbai Police, who sets out to curb the city's rampant drug-trafficking and prostitution. When he uncovers a deep controversy linked to an international drug lord, however, he tries to fulfill his secret agenda. The film is Rajinikanth's first role as a police officer in 27 years following Pandiyan (1992). The project's working title was Thalaivar 167 and the title Darbar was officially announced on 9 April 2019. Principal photography commenced the same month, mostly in Mumbai, and was completed in October 2019. Anirudh Ravichander composed the music for the film. The cinematographer was Santosh Sivan and the editor was A. Sreekar Prasad. Darbar was released theatrically in India on 9 January 2020, coinciding with the Pongal festival. The film met with mixed reviews upon release with praise for Rajinikanth’s performance and grossed ₹250 crore at the box office, making it the highest-grossing Tamil film of 2020 and 4th highest-grossing Indian film of 2020. Darbar became Rajinikanth’s fifth film to gross over ₹200 crore worldwide, following Enthiran, Kabali, 2.0, and Petta.
Sources: en.wikipedia.org
British Somaliland obtained independence on 26 June 1960, and Italian Somaliland followed on 1 July, with the two uniting to form the Somali Republic, within boundaries drawn up by Italy and Britain. A government was formed by members of the former trusteeship and protectorate governments, with Abdulcadir Muhammed Aden as President of the Somali National Assembly, Aden Abdullah Osman Daar as President of the Somali Republic, and Abdirashid Ali Shermarke as Prime Minister (later to become president from 1967 to 1969). On 20 July 1961, a popular referendum, was ratified by the people of Italian Somalia. Most people did not participate, although only a small number voted against the new constitution. In 1967, Muhammad Haji Ibrahim Egal became Prime Minister, a position to which he was appointed by Shermarke. Egal would later become the President of the autonomous Somaliland region in northwestern Somalia.
== Toxicity == All Datura plants contain tropane alkaloids such as scopolamine and atropine, primarily in their seeds and flowers, as well as the roots of certain species such as D. wrightii. Because of the presence of these substances, Datura has been used for centuries in some cultures as a poison. A given plant's toxicity depends on its age, where it is growing, and the local weather conditions. These variations make Datura exceptionally hazardous as a drug. Since datura directly causes the effects of anticholinergic syndrome, the symptoms of its toxicity are often cited by the traditional mnemonic: "Blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone, the bowel and bladder lose their tone, and the heart runs alone". Datura, as well as long-term psychoactive/toxic usage of other anticholinergic drugs, also appear to significantly increase the risk of developing dementia. In traditional cultures, a great deal of experience with and detailed knowledge of Datura was critical to minimize harm. Many tragic incidents result from modern users ingesting or smoking Datura. For example, in the 1990s and 2000s, the United States media reported stories of adolescents and young adults dying or becoming seriously ill from intentionally ingesting Datura. Deliberate or inadvertent poisoning resulting from smoking jimsonweed and other related species has been reported as well. Although most poisonings occur with more common species of Datura such as D. stramonium, several reports in the medical literature indicate deaths from D. ferox intoxication.
==== Motivational disorders ==== In animal studies, modafinil has been found to reverse tetrabenazine-induced motivational deficits, suggesting potential pro-motivational effects. Novel modafinil analogs are being developed as potential treatments for motivational disorders in humans.
The N-terminus (also known as the amino-terminus, NH2-terminus, N-terminal end or amine-terminus) is the start of a protein or polypeptide, referring to the free amine group (-NH2) located at the end of a polypeptide. Within a peptide, the amine group is bonded to the carboxylic group of another amino acid, making it a chain. That leaves a free carboxylic group at one end of the peptide, called the C-terminus, and a free amine group on the other end called the N-terminus. By convention, peptide sequences are written N-terminus to C-terminus, left to right (in LTR writing systems). This correlates the translation direction to the text direction, because when a protein is translated from messenger RNA, it is created from the N-terminus to the C-terminus, as amino acids are added to the carboxyl end of the protein.
Sources: en.wikipedia.org
Myxedema coma is a rare but life-threatening state of extreme hypothyroidism. It may occur in those with established hypothyroidism when they develop an acute illness. Myxedema coma can be the first presentation of hypothyroidism. People with myxedema coma typically have a low body temperature without shivering, confusion, a slow heart rate and reduced breathing effort. There may be physical signs suggestive of hypothyroidism, such as skin changes or enlargement of the tongue.
The cord is a unit of measure of dry volume used in Canada and the United States to measure firewood and pulpwood. A cord is the amount of wood that, when "ranked and well stowed" (arranged so pieces are aligned, parallel, touching and compact), occupies a volume of 128 cubic feet (3.62 m3). This corresponds to a well-stacked woodpile, 4 feet deep by 4 feet high by 8 feet wide (122 cm × 122 cm × 244 cm), or any other arrangement of linear measurements that yields the same volume. A more unusual measurement for firewood is the "rick" or face cord. It is stacked 16 inches (40.6 cm) deep with the other measurements kept the same as a cord, making it 1⁄3 of a cord; however, regional variations mean that its precise definition is non-standardized.
recent surgery (both for thromboembolism and air embolism) previous stroke or cardiovascular disease a history of long-term intravenous therapy (for air embolism) Bone fracture (for fat embolism) A septal defect of the heart makes it possible for paradoxical embolization, which happens when a clot in a vein enters the right side of the heart and passes through a hole into the left side. The clot can then move to an artery and cause arterial embolisation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.